Thursday, May 18 | 10 – 11 a.m. ET | Online

Rapid advances and decreasing costs of human genome sequencing technologies are accelerating the integration of genomics into clinical practice. Although genomic sequencing has demonstrated utility as an indication-based diagnostic tool for certain diseases, the full potential of DNA sequencing for population-level screening is yet to be realized. DNA-based population screening has enormous potential to identify people with underlying genetic predisposition to serious diseases such as cancer and heart disease, who represent 1–2% of the population. Early detection, disease prevention, and timely treatment can improve health outcomes and equity, and usher in a new era of precision public health.

Learn more and register for this webinar on the CDC Genomics and Precision Health website.

Speakers:

Jonathan S. Berg, MD, PhD
Bryson Distinguished Professor, Genetics and Medicine
University of North Carolina
Chapel Hill, North Carolina

Laura Milko, PhD
Assistant Professor, Genetics
University of North Carolina
Chapel Hill, North Carolina